4.05
-0.11 (-2.64%)
| Previous Close | 4.16 |
| Open | 4.10 |
| Volume | 1,688,826 |
| Avg. Volume (3M) | 10,056,401 |
| Market Cap | 316,126,208 |
| Price / Book | 1.08 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Replimune Group, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.88 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (JP Morgan, 122.22%) | Hold |
| Median | 3.50 (-13.58%) | |
| Low | 2.00 (BMO Capital, -50.62%) | Sell |
| Average | 4.50 (11.11%) | |
| Total | 1 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 2.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 23 Jul 2025 | 2.00 (-50.62%) | Sell | 3.34 |
| Barclays | 23 Jul 2025 | 3.00 (-25.93%) | Hold | 3.34 |
| JP Morgan | 22 Jul 2025 | 9.00 (122.22%) | Hold | 2.81 |
| Jefferies | 22 Jul 2025 | 6.00 (48.15%) | Buy | 2.81 |
| Leerink Partners | 22 Jul 2025 | 3.00 (-25.93%) | Hold | 2.81 |
| Wedbush | 22 Jul 2025 | 4.00 (-1.23%) | Hold | 2.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |